The combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was the first BRAF/MEK inhibitor combination to be approved for the treatment of advanced melanoma in the USA in 2014, and in the EU in 2015. The gene discussed is BRAF; the disease is melanoma.